Chemical exchange saturation transfer MRI signal loss of the substantia Nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease

Chunmei Li, Min Chen, Xuna Zhao, Rui Wang, Haibo Chen, Wen Su, Shuhua Li, Baohui Lou, Guodong Song, Shuai Zhang, Jintao Zhang, Jinyuan Zhou

Research output: Contribution to journalArticle

Abstract

The early diagnosis of Parkinson's disease (PD) and the accurate evaluation of disease severity are crucial for intervention and treatment in PD patients. In this study, we applied chemical exchange saturation transfer (CEST) imaging to patients at different stages of PD and explored the clinical value of the CEST signal loss of the substantia nigra as an imaging biomarker of PD. The measured CEST signal intensities (including amide proton transfer-weighted or APTw, and total CEST or CESTtotal) of the substantia nigra in PD patients showed a significantly decreased tendency with PD progression. Compared to normal controls, the APTw and CESTtotal intensities of PD patients significantly decreased at both the early and advanced or late stages. These APTw and CESTtotal values of the substantia nigra were also significantly lower in advanced or late stage PD patients than in early stage PD patients. For PD patients with unilateral symptoms, the APTw and CESTtotal values in the substantia nigra on the affected side were significantly lower than those in normal controls. Both the APTw and CESTtotal values of PD were significantly correlated with the severity of disease and disease duration. Our findings suggest that the CEST MRI signal of the substantia nigra is a potential imaging biomarker for the diagnosis and monitoring of the severity of PD.

Original languageEnglish (US)
Article number489
JournalFrontiers in Neuroscience
Volume11
Issue numberAUG
DOIs
StatePublished - Aug 31 2017

Fingerprint

Substantia Nigra
Parkinson Disease
Biomarkers
Amides
Disease Progression
Protons
Early Diagnosis

Keywords

  • APT imaging
  • Biomarker
  • CEST imaging
  • Parkinson's disease
  • Substantia nigra

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Chemical exchange saturation transfer MRI signal loss of the substantia Nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease. / Li, Chunmei; Chen, Min; Zhao, Xuna; Wang, Rui; Chen, Haibo; Su, Wen; Li, Shuhua; Lou, Baohui; Song, Guodong; Zhang, Shuai; Zhang, Jintao; Zhou, Jinyuan.

In: Frontiers in Neuroscience, Vol. 11, No. AUG, 489, 31.08.2017.

Research output: Contribution to journalArticle

Li, Chunmei ; Chen, Min ; Zhao, Xuna ; Wang, Rui ; Chen, Haibo ; Su, Wen ; Li, Shuhua ; Lou, Baohui ; Song, Guodong ; Zhang, Shuai ; Zhang, Jintao ; Zhou, Jinyuan. / Chemical exchange saturation transfer MRI signal loss of the substantia Nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease. In: Frontiers in Neuroscience. 2017 ; Vol. 11, No. AUG.
@article{081911aa0ca14509823088e694885855,
title = "Chemical exchange saturation transfer MRI signal loss of the substantia Nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease",
abstract = "The early diagnosis of Parkinson's disease (PD) and the accurate evaluation of disease severity are crucial for intervention and treatment in PD patients. In this study, we applied chemical exchange saturation transfer (CEST) imaging to patients at different stages of PD and explored the clinical value of the CEST signal loss of the substantia nigra as an imaging biomarker of PD. The measured CEST signal intensities (including amide proton transfer-weighted or APTw, and total CEST or CESTtotal) of the substantia nigra in PD patients showed a significantly decreased tendency with PD progression. Compared to normal controls, the APTw and CESTtotal intensities of PD patients significantly decreased at both the early and advanced or late stages. These APTw and CESTtotal values of the substantia nigra were also significantly lower in advanced or late stage PD patients than in early stage PD patients. For PD patients with unilateral symptoms, the APTw and CESTtotal values in the substantia nigra on the affected side were significantly lower than those in normal controls. Both the APTw and CESTtotal values of PD were significantly correlated with the severity of disease and disease duration. Our findings suggest that the CEST MRI signal of the substantia nigra is a potential imaging biomarker for the diagnosis and monitoring of the severity of PD.",
keywords = "APT imaging, Biomarker, CEST imaging, Parkinson's disease, Substantia nigra",
author = "Chunmei Li and Min Chen and Xuna Zhao and Rui Wang and Haibo Chen and Wen Su and Shuhua Li and Baohui Lou and Guodong Song and Shuai Zhang and Jintao Zhang and Jinyuan Zhou",
year = "2017",
month = "8",
day = "31",
doi = "10.3389/fnins.2017.00489",
language = "English (US)",
volume = "11",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "AUG",

}

TY - JOUR

T1 - Chemical exchange saturation transfer MRI signal loss of the substantia Nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease

AU - Li, Chunmei

AU - Chen, Min

AU - Zhao, Xuna

AU - Wang, Rui

AU - Chen, Haibo

AU - Su, Wen

AU - Li, Shuhua

AU - Lou, Baohui

AU - Song, Guodong

AU - Zhang, Shuai

AU - Zhang, Jintao

AU - Zhou, Jinyuan

PY - 2017/8/31

Y1 - 2017/8/31

N2 - The early diagnosis of Parkinson's disease (PD) and the accurate evaluation of disease severity are crucial for intervention and treatment in PD patients. In this study, we applied chemical exchange saturation transfer (CEST) imaging to patients at different stages of PD and explored the clinical value of the CEST signal loss of the substantia nigra as an imaging biomarker of PD. The measured CEST signal intensities (including amide proton transfer-weighted or APTw, and total CEST or CESTtotal) of the substantia nigra in PD patients showed a significantly decreased tendency with PD progression. Compared to normal controls, the APTw and CESTtotal intensities of PD patients significantly decreased at both the early and advanced or late stages. These APTw and CESTtotal values of the substantia nigra were also significantly lower in advanced or late stage PD patients than in early stage PD patients. For PD patients with unilateral symptoms, the APTw and CESTtotal values in the substantia nigra on the affected side were significantly lower than those in normal controls. Both the APTw and CESTtotal values of PD were significantly correlated with the severity of disease and disease duration. Our findings suggest that the CEST MRI signal of the substantia nigra is a potential imaging biomarker for the diagnosis and monitoring of the severity of PD.

AB - The early diagnosis of Parkinson's disease (PD) and the accurate evaluation of disease severity are crucial for intervention and treatment in PD patients. In this study, we applied chemical exchange saturation transfer (CEST) imaging to patients at different stages of PD and explored the clinical value of the CEST signal loss of the substantia nigra as an imaging biomarker of PD. The measured CEST signal intensities (including amide proton transfer-weighted or APTw, and total CEST or CESTtotal) of the substantia nigra in PD patients showed a significantly decreased tendency with PD progression. Compared to normal controls, the APTw and CESTtotal intensities of PD patients significantly decreased at both the early and advanced or late stages. These APTw and CESTtotal values of the substantia nigra were also significantly lower in advanced or late stage PD patients than in early stage PD patients. For PD patients with unilateral symptoms, the APTw and CESTtotal values in the substantia nigra on the affected side were significantly lower than those in normal controls. Both the APTw and CESTtotal values of PD were significantly correlated with the severity of disease and disease duration. Our findings suggest that the CEST MRI signal of the substantia nigra is a potential imaging biomarker for the diagnosis and monitoring of the severity of PD.

KW - APT imaging

KW - Biomarker

KW - CEST imaging

KW - Parkinson's disease

KW - Substantia nigra

UR - http://www.scopus.com/inward/record.url?scp=85043760853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043760853&partnerID=8YFLogxK

U2 - 10.3389/fnins.2017.00489

DO - 10.3389/fnins.2017.00489

M3 - Article

C2 - 28912676

AN - SCOPUS:85043760853

VL - 11

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - AUG

M1 - 489

ER -